Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $251.06

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $239.8667.

Several research firms recently weighed in on IQV. Citigroup cut their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday. Evercore ISI reaffirmed an “outperform” rating on shares of IQVIA in a research report on Thursday. Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday.

IQVIA Price Performance

Shares of NYSE:IQV opened at $192.58 on Thursday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. The stock has a market capitalization of $32.80 billion, a P/E ratio of 24.50, a P/E/G ratio of 1.90 and a beta of 1.37. The business has a 50-day moving average of $227.31 and a two-hundred day moving average of $209.81. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Large investors have recently made changes to their positions in the stock. Boston Partners purchased a new position in shares of IQVIA in the 3rd quarter valued at about $676,698,000. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA in the second quarter valued at $515,772,000. Norges Bank acquired a new stake in shares of IQVIA during the second quarter valued at $270,160,000. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares during the period. Finally, Laurel Wealth Advisors LLC grew its holdings in IQVIA by 15,755.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after buying an additional 774,681 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.